A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks
← catalyst calendarNCT07752407 · readout in 426 d
Sponsored by Phathom Pharmaceuticals, Inc. (industry) · PHAT — their whole pipeline →.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
500estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-09-25 | estimated | When the study began enrolling |
| Primary completion | 2027-10-20 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-01-19 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Symptomatic Non-erosive Gastroesophageal Reflux Disease
Interventions
- Drug: Vonoprazan
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFPercentage of Treated Heartburn Episodes Achieving Complete Relief at 2 Hours and Sustained Relief for 24 Hours up to Week 12
measured Up to Week 12
Permalink · PHAT's whole pipeline · Catalyst calendar · Every registered study · What changed